SCHEMBL27218931

SCHEMBL27218931

Cc1coc(SCc2nc(-c3ccc4c(c3)OCO4)no2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.49
▸ MAPT P10636 6/20 0.48
▸ SMN1; SMN2 Q16637 6/20 0.48
▸ RAB9A P51151 10/20 0.46
▸ TSHR P16473 2/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ NPC1 O15118 8/20 0.45
▸ PKM P14618 1/20 0.45
▸ CHRM2 P08172 1/20 0.45
▸ CHRM5 P08912 1/20 0.45
▸ CHRM1 P11229 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ NFKB1 P19838 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27218909 0.88 MAPT (0.46) GAAMAPTSMN1; SMN2RAB9ATSHR
SCHEMBL31494458 0.84 RAB9A (0.54) GAAMAPTSMN1; SMN2RAB9ATSHR
SCHEMBL27218781 0.84 NPC1 (0.54) GAAMAPTSMN1; SMN2RAB9ATSHR
SCHEMBL27218818 0.83 MAPT (0.53) GAAMAPTSMN1; SMN2RAB9ATSHR
SCHEMBL27218916 0.83 MAPT (0.50) GAAMAPTSMN1; SMN2RAB9ATSHR
SCHEMBL31494422 0.82 RAB9A (0.55) GAAMAPTSMN1; SMN2RAB9ATSHR
SCHEMBL31494419 0.82 NPC1 (0.46) GAAMAPTSMN1; SMN2RAB9ATSHR
SCHEMBL27218797 0.81 MAPT (0.44) GAAMAPTSMN1; SMN2RAB9ATSHR
SCHEMBL31494420 0.81 GAA (0.48) GAAMAPTSMN1; SMN2RAB9ATSHR
SCHEMBL31494362 0.81 GAA (0.51) GAAMAPTSMN1; SMN2RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 GAA 1479/4885MAPT 4802/4885SMN1; SMN2 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback